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Abstract
To better understand effects of exposure to food allergens, food chal-
lenge studies are designed to slowly increase the dose of an allergen de-
livered to allergic individuals until an objective reaction occurs. These
dose-to-failure studies are used to determine acceptable intake levels and
are analyzed using parametric failure time models. Though these mod-
els can provide estimates of the survival curve, their parametric form may
misrepresent the survival function for doses of interest, and different mod-
els that describe the data similarly may produce different dose-to-failure
estimates. Motivated by predictive inference, we developed a Bayesian
approach to combine survival estimates based upon posterior predictive
stacking, where the weights are formed to maximize posterior predictive
accuracy. The approach allows for the inclusion of flexible models, and,
in our case, allows us to include random effects to account for frailty com-
ponents entering the model through study-to-study heterogeneity. The
methodology is investigated in simulation, and is used to estimate allergic
population eliciting doses for multiple food allergens.
Keywords:Accelerated Failure Time Models, Ensemble Learning, Ran-
dom Effects, Model Averaging
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1 Introduction
Interval censored failure time data can be found in many areas of research
including animal carcinogenicity experiments, demographical, epidemiological,
financial, medical, sociological, machine reliability, and injury risk studies (Col-
lett, 2015; Crowder et al., 1994; Klein et al., 2016; Ozturk et al., 2018; Sun, 2006;
Yoganandan et al., 2016). Typical examples of interval censored data are found
in medical or health studies with periodic follow-up protocols, with examples
including time-to-tumor or time-to-infection studies (e.g. appearance of lung
cancer tumors; breast cancer studies with 4-6 month follow-up times; timing
of HIV infection in AIDS cohort studies with follow-up every 6 months) (Sun,
2006). Another example of interval censored failure time data can be found
in the dosing steps of an oral food challenge studies to diagnose food allergy
Taylor et al. [2009]. However, the previously available methods for parametric
modelling of interval censored failure data have been limited to single model
approaches. In other fields of risk assessment, i.e. chemical risk assessment,
single model selection and rejection has been acknowledged as a suboptimal ap-
proach and a more advanced, state-of-the-art method preferred for parametric
modelling is model averaging (EFSA Scientific Committee, 2017; US EPA et
al., 2019). Current model averaging methods available for chemical benchmark
dose risk assessment are limited to a single dose or time point and corresponding
model averaging techniques for interval censored data have not been previously
available. In this study, we present a novel Bayesian methodology developed
for interval censored failure data to combine parametric survival estimates with
frailty components based upon posterior predictive stacking, where the weights
are formed to maximize posterior predictive accuracy. The case study of oral
food challenge data from food allergic patients is utilized to demonstrate the
utility of the method.
In studying food allergies, oral food challenge studies slowly increase the
food protein dose until the individual presents allergic symptoms to a specific
exposure amount (mg food protein). Figure (1) shows an example of such data
for peanut allergies and represents 17 different clinical studies. Each study can
range in size, from a small (10 to 30 participants) to a large (over 200 par-
ticipants) dose-to-failure experiment with participants who present with objec-
tive, externally observable symptoms. To more accurately estimate the survival
curve, separate studies are combined to estimate an exposed dose that repre-
sents a predefined, specific risk to the population. Risk assessors are typically
interested in finding allergic population-based eliciting doses (EDs) where less
than 1% or 5% of the allergic population would experience an objective allergic
reaction (ED01, ED05 respectively). Such data are most appropriately analyzed
using survival techniques [Crevel et al., 2007, Taylor et al., 2009, 2014, Dano
et al., 2015] , but to accurately represent the population’s dose-to-failure distri-
bution, especially in the lower tails, use of a single survival distribution presents
several challenges.
Most critically, we are concerned with survival regression methods that pro-
vide an accurate representation of the dose-to-failure curve along with appropri-
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ate uncertainties being accurately represented. Traditionally, a non-parametric
estimator, such as the Kaplan-Meier [Turnbull, 1976], can be used for this task.
However, food challenge data is not readily available for all foods, geographic lo-
cations, age groups or other sub-populations. Thus, the data sets of interest can
typically rely on less than 100 observations where the true dose-at-failure is only
known to be in an interval (i.e., the data are interval censored). Non-parametric
estimators, based on such limited data, may not be able to accurately capture
dose-to-failure distribution in the tails of the failure distribution.
Parametric failure time models are an alternative to non-parametric survival
models if they fit the data well. In many cases, this is not the case, and these
models may not be flexible enough, especially in the tails of the failure distribu-
tion, to describe a given data set. As a consequence, estimation using any single
model may result in bias and estimates whose parameters do not fully reflect
the true uncertainty. With this in mind, a number of authors have considered
flexible parametric survival models using mixing distributions. Lambert et al.
Lambert et al. [2004] used a mixture distribution consisting of a Gompertz haz-
ard function and a single accelerated failure time (AFT) component. Komarek
and Lesaffare Koma´rek and Lesaffre [2008] developed an AFT model with an
over-specified number of mixture components. In both cases, the resulting time
to failure distribution is a convex sum of individual failure curves, which is
more flexible than a single parametric model, but these approaches develop a
new class of models to describe the data, under the assumption the increased
flexibility will accurately describe the observed data. As a consequence, given
appropriate data, the methodologies may suffer from the same issues as single
failure time distributions. Instead of creating a new survival model, we take
the approach that it is possible to estimate the survival function as a weighted
sum of the posterior distribution of existing parametric failure models. As our
approach is a general methodology it could incorporate any failure model, which
includes those of Lambert et al. and Komarek and Lesaffare.
Unlike the above mixture approaches, we estimate failure distributions indi-
vidually and focus on estimation where the failure distribution is representable
as a convex sum of these estimates. This is often accomplished using Bayesian
model averaging [Raftery et al., 1997, Hoeting et al., 1999] (BMA). However,
when the true data generating mechanism is not in the suite of models consid-
ered BMA may not be appropriate. BMA is known to choose the model that
is closest in Kullback-Leibler divergence to the observed data generating mech-
anism [Yao et al., 2018], which implies that the estimate will asymptotically
be from one model. In our problem, there is no expectation that any of the
parametric survival curves represent the true survival function, implying the es-
timate will be chosen by a single incorrect model that does not fully incorporate
all of the uncertainty.
Instead of picking the best model that represents the data, we are interested
in finding a set of weights that optimize posterior predictive inference. Stacking
[Wolpert, 1992, Breiman, 1996, LeBlanc and Tibshirani, 1996] produces esti-
mates based upon multiple models, but focuses on predicting new observations
based upon some scoring rule. Here point estimates and uncertainty in that
3
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Figure 1: Individual Kaplan-Meier curves for 17 food challenge studies investi-
gating Peanut protein sensitized populations. The darker red curves represent
studies with more observations.
estimate are constructed using a weighted average of estimates, where weights
are formed by minimizing the squared error scoring rule in a leave-one-out cross
validation. Originally used in frequentist settings, stacking has been given a
Bayesian motivation by Clyde and Iverson Clyde and Iversen [2013]. They
show that weights can be interpreted as maximizing the expected utility under
several loss functions for the prediction of new data; Le and Clarke Le et al.
[2017] show that the stacking solution is the Bayes solution asymptotically, but,
these results limit stacking to averaging point predictions. Yao et al. Yao et al.
[2018] extend these results making stacking applicable to estimating the poste-
rior predictive distribution. We apply Yao et al. to stack posterior predictive
distributions estimated from parametric failure time modeling. This results in
a flexible methodology to estimate the failure distribution using any fit para-
metric model, where no single model is expected to get weight 1 as the sample
size increases. The methodology is relatively straightforward to implement and
extend using a new parametric failure model in STAN [Carpenter et al., 2017],
and we provide an R package that implements the modeling for the data we
consider.
As any parametric model can be used with this methodology, we include
frailty components through random effects to account for study-to-study hetero-
geneity. This approach has a long history of use in both semi-parametric [Klein,
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1992] and parametric [Vaida and Xu, 2000, Yamaguchi et al., 2002, Koma´rek
et al., 2007, Crowther et al., 2014] time-to-event data to represent frailty compo-
nents. In our data, our effects enter the model as study specific random effects,
where the frailties are thought to arise through: differing protocols, differing
participant recruitment, differing cumulative dosing designs, differing symptom
interpretations by clinicians and nurses, and an array of possible regional genetic
or environmental differences present in each study’s population. In addition to
frailty components with standard right- and left- censoring, we include the pos-
sibility that the failure is only known in an interval to reflect the complicated
nature of our data problem. This is a flexible approach to analyzing failure time
data that arise from a diverse set of circumstances.
The manuscript is organized by describing the general model framework,
studying the method through a simulation, and showing the utility of the
method by applying it to two food allergen dose-to-failure databases. Exam-
ple databases for the manuscript include a large peanut allergy food challenge
database Taylor et al. [2014] and much smaller sesame allergy food challenge
database Dano et al. [2015] formed from multiple studies at different centers.
2 Stacked Survival Regression
To model these data, assume there are J studies and each study has nj ob-
servations, where j = 1, . . . , J . For subject i , i = 1, . . . , nj , in study j, we
observe a failure in the interval τ(ij) = [ti1, ti2] = [ajk, aj(k+1)], where the set
{ajk}Kj+1k=1 , ajk < aj(k+1), represents Kj+1 study specific intervals where the
failure can be observed, cumulative dose intervals in our case. For k = 1,
aj1 = 0 and for k = Kj + 1 one has aj(Kj+1) = ∞. For J studies, we observe
T = {τ(11), . . . , τ(nj1), . . . , τ(1J), . . . , τ(nJJ)} with n =
∑J
j=1 nj total observa-
tions and wish to accurately estimate the underlying generating process.
Let F (t|µ(x), λ) be a cumulative distribution function (CDF), with µ(x) a
function of x defining the location and λ a scale parameter. Given the failure
model F (t|µ(x), λ) and noting S(t | µ(x), λ, x) = 1−F (t | µ(x), λ), the observed
data likelihood for T is
`(T |µ(x), λ) =
j∏
j=1
nj∏
i=1
{
F (ti2 | µ(xij), λ)− F (ti1 | µ(xij), λ)
}
, (1)
where xij is a vector of covariates.
For a given F (t | µ(x), λ), (1) forms a key component for inference on the
failure distribution, and µ(x) may include fixed and random effects. In our
problem, x is a vector of indicator variables that indicate the observation’s
study and is related to µ(x) through the identity or log link of Bx, where
B = (b0, . . . , bj)
′ and b0 is a fixed intercept. That is, for study j given CDF
F (t|·), µ(xj) = b0 + bj or µ(xj) = exp(b0 + bj), which is used to define a random
effect model over the study centers.
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When random effects are included in the model, inference on the population
average survivor function may be of interest. This quantity is estimated by
marginalizing over µ., i.e.,
S(t | λ, x) =
∫
S(t | µ(x), λ)dµ. (2)
For many survival functions, analytic evaluation of this integral is not possible.
In what follows, we estimate it using Markov Chain Monte Carlo (MCMC)
methods.
The above describes a likelihood model on a specific failure distribution that
can be used in Bayesian or frequentist inference. Given a CDF, there is no
expectation that any parametric failure distribution will be representative of
the underlying process. In what follows, we use Bayesian stacking to estimate
the failure distribution from multiple parametric models that can be analyzed
individually using (1) as well as prior assumptions on using Bayesian stacking.
2.1 Bayesian Stacked Survival
For inference based upon an individual survival function, we place a prior over
µ(x) and λ and estimate the posterior distribution using MCMC. Inference on
a single model may under represent the true uncertainty around the failure
distribution. Consequently, we perform multi-model inference using Bayesian
stacking.
Assume there are M individual failure distributions, i.e., Fm(t|µm(x), λm),
m = 1, . . . ,M , estimated using MCMC. We wish to find an optimal predictive
distribution for F (t|x) and S(t|x) based upon these M models. To do this, we
use Yao et al. [2018] to estimate a set of optimal weights that places F (t|x) and
S(t|x) in the convex hull of the M posterior predictive densities. That is we
find wˆ = (wˆ1, . . . , wˆM ) and estimate the predictive density for new failure time
t˜ as
pˆ(t˜|T, x) =
M∑
m=1
wˆmpm(t˜|T, x), (3)
where pm(t˜ | T, x) is the posterior predictive distribution for model m.
As discussed in Yao et al. [2018], the weights are found by
wˆ = argmax
w∈Ω
1
n
J∑
j=1
nj∑
i=1
log
[ M∑
m=1
wmpm(τij |T−(ij))
]
,
where pm(τij | T−(ij)) is the leave-one-out predictive distribution computed
using PSIS-LOO Vehtari et al. [2017] and Ω is the space weights such that∑M
m=1 wm = 1. By estimating the posterior predictive distribution in (3) a
large number of plausible failure time distributions can be investigated, and
uncertainty in the true failure distribution can be appropriately expressed. Fur-
ther, this can be readily implemented in off the shelf software, which allows for
straightforward implementation of the approach.
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2.2 Estimation
Individual model estimation proceeds using MCMC and the No-U-Turn Sampler
(NUTS) [Hoffman and Gelman, 2014] implemented in STAN Carpenter et al.
[2017]. These posterior samples are used to estimate the stacked survival func-
tion. With (3) sampled using MCMC, there are several survival functions that
may be of interest. If it is believed that an individual study may be representa-
tive of a susceptible sub-population, i.e., a representative of a group that may
be particularly susceptible to failure, then the expected survival distribution for
a given study can be computed as
E
[
Sj(t˜ | T, xj) | T
]
=
M∑
m=1
∫
I(t > t˜)wˆmpˆm(t | T, xj)dµ(j)dλ(j)dt,
where µ(j) and λ(j) is shorthand to represent sampled parameter vectors for
all M models given the data T , that is these values are available from the
sampling output. This gives the point wise posterior predicted survival curve
for an individual study with information shared between studies through the
parameters.
To estimate the population average survival function, the frailty components
should be accounted for, which is accomplished by integrating out the random
effects, i.e.
E
[
S(t˜ | T, x) | T
]
=
M∑
m=1
∫
I(t > t˜)wˆmpm(t|T, x) dµm dλm dt,
which is estimable over MCMC iterations.
All estimates form the point-wise survival curve estimates. To compute the
survival curve over the interval (0, A], we estimate the point-wise curve over
a fine grid of points and use a spline function to interpolate between points.
Specific time-to-failure probabilities are then computed from this curve. For ex-
ample, in our application the eliciting dose (ED) causing a group or population
to have y percent failure, i.e. EDy is computed from the spline estimate. Fur-
ther, posterior predictive summaries of this value , e.g., distribution quantiles,
can also be computed similarly as above.
3 Bayesian Specification
3.1 Failure Distributions
The above specification is general and may include any density; however, for this
analysis, we choose each Fm(·) from M distributions that are either common in
parametric survival regression, i.e., the Weibull distribution and Log-Gaussian
(Log-Normal) and Log-Logistic, or whose mean µm is easily represented as a lin-
ear or exponential function of x; additionally we include the generalized Pareto
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and Log-Laplace, also known as the log double-exponential, distribution, which
have heavy tails, and are not typically used in the survival literature. These
choices give a broad range of survival functions that are applicable to many
contexts, but the methodology is easily extended to other models if necessary.
Table (1 ) gives the five parametric distributions chosen in this specification.
All of the distributions are determined by a µ(x) and a scale parameter λ.
Distribution F [t|µ(x), λ] µ(x)
Weibull 1− exp
[
−
(
t
µ(x)
)λ]
exp(−bx)
Generalized Pareto λµ(x)
(
1 + tµ(x)
)−(λ+1)
exp(bx)
Log-Gaussian Φ
[
log(t)−µ
λ
]
bx
Log-Logistic 1
1+[t/µ(x)]−λ exp(−bx)
Log-Laplace 12
[
1 + sgn
(
log{t} − µ(x)
)(
1− exp
{
− | log[y]− µ(x) | /λ
})]
bx
Table 1: Models and parameters used as failure time distributions in the anal-
ysis,.
3.2 Prior Specifications
We place diffuse priors over a range of plausible shapes for each distribution
defined above. For any given analysis, the observed failure times are typically
on different scales. For example, cancer recurrence times may be in the tens
of years where as cumulative dose-to-failure data may be in the thousands of
micro-grams; specifying a prior for a given failure distribution Fm(·) on a given
scale may not translate to another scale. To create a general approach, we
scale all failure times to be in the [0, 1] interval. Diffuse priors are subsequently
defined relative to this interval.
Table (2) describes the priors for the each model. For each survival function,
b0 defines mean of the random effects distribution placed over b in Table (1),
where b ∼ N(b0, z) and z is a hyperparamter on the variance of the random effect
specific to the distribution. For a given model, the dispersion parameter λ is
given a prior that is diffuse over the interval [0, 1]. For example in the Weibull
model, the shape parameter λ is log normal allowing a large range of shapes
in this range, but for the Log-Gaussian this parameter is given a Gamma(1, 1)
distribution.
4 Simulation
We investigated the performance of this approach through simulation. For this
study, we use the priors defined above, and, as we are concerned with inference
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Model b0 b z λ
Weibull Cauchy(0, 1) N(b0, z) IG(1, 1) LN(0,
√
0.25))
Generalized Pareto Cauchy(0, 1) N(0,
√
z) IG(1, 1) Gamma(2, 1)
Log-Gaussian Cauchy(0, 1) N(b0,
√
z) IG(1, 1) Gamma(1, 1)
Log-Logistic Cauchy(0, 1) N(b0,
√
z) IG(0.1, 0.1)1[0<z<4] LN(0, 1)
Log-Laplace Cauchy(0, 1) N(b0, z) IG(0.1, 0.1)1[0<z<4] LN(0, 1)
Table 2: Priors defined for each failure model. Distributions are specified such
that N(µ, σ) represents the normal distribution with mean µ and standard devi-
ation σ, IG(a, b) is the inverse-gamma distribution with parameters a and b, and
LN(µ, σ) is the log-normal distribution with log-mean µ and standard-deviation
σ. Additionally, 1[c<x<d] is an indicator function truncating the random variable
x to be in the interval [c, d].
in the tail of the dose-to-failure curve for food allergy related purposes, we look
at estimating the doses associated with 0.01, 0.05, and 0.10 failure rates. We
compare the proposed approach to a Weibull model with a random effect term
specified for each study.
For the simulation, data are generated from two underlying true failure dis-
tributions,
F1(d|µ(x)w, µ(x)IG, ) = 0.7 Weibull(µ(x)w, 10) + 0.3 IG(µ(x)IG, 0.25)
F2(d|µ(x)IG, µ(x)ST ) = 0.5 IG(µ(x)IG, 0.25) + 0.5 log-SkewT(µ(x)ST , 1, 3),
which represent mixture distribution from two distinct failure models depen-
dent on study x. Here, IG is the CDF of the inverse-Gaussian distribution
having expectation µ(x)IG and scale 0.25, and log-SkewT is the CDF of log of
the skew-T distribution, that is if D ∼ log-SkewT(µ(x)ST , 1, 3) then log(D) ∼
SkewT(µ(x)ST , 1, 3) where µ(x) is the center parameter, 1 is the dispersion pa-
rameter, and 3 is the skew parameter. By defining the failure distribution to be
a mixture distribution, the study ensures the true failure distribution is not in
the suite of distributions fit to the data; however, F1(d|·) is close to the Weibull
model that is fit to the data as a comparison. This allows a comparison of
the robustness of inference when the model is slightly miss-specified. Further,
F2(d|·) is a case where the model is completely miss-specified, which allows a
comparison of the methodologies in cases expected to arise in practice.
To accommodate study-to-study variability, multiple study centers are in-
cluded in each simulation. For each iteration and distribution/study, µ(x) is
drawn from a log-Gaussian distribution with log-standard deviation of 0.25 and
log-mean of 1, 7 and −0.8 for the Weibull, inverse-Gaussian, and log-Skew T dis-
tributions respectively. This process was done 200 times for n = 5, 15, 30 study
centers. For each study center, a random number of subjects were observed,
where the total number of subjects was drawn from a Poisson distribution with
mean 10. Additionally, the interval censoring locations were considered random
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for each study. Here 10 dosing regimes were drawn from a log-Gaussian distri-
bution with log mean of 1 and log-standard deviation of 1.4. To ensure these
doses were not close to zero, i.e. there was appreciable positive probability of
a left censoring event, 0.75 was added to each tested dose. The dose-to-failure
was estimated for probabilities 1, 5, and 10%, and the mean squared integrated
error for the proposed approach and the Weibull approach are computed.
Table (3) gives the ratio of the mean squared error (MSE) between the two
approaches. Values less than one indicate the proposed approach has less mean
squared error, while asterisks indicate that ratio is significantly different at the
α = 0.05 level. In the case of the inverse-Gaussian/log-Skew T case, which is the
case the model is completely mis-specified, the proposed approach has signifi-
cantly less MSE than the Weibull approach. Further, the improvement increases
as the number of study centers increases, which indicates that the difference in
the MSE improves as more study centers are added. In the Weibull/inverse-
Gaussian case, a more nuanced result is seen. Here the MSE is approximately
the same between the two approaches, when n = 5 and n = 15, but does fa-
vor fitting the single Weibull model when n = 30. for smaller sample with the
Weibull random effects model appearing to have slightly less MSE although
this value is never significantly different at the 0.05 level across the simulation
conditions.
Inverse-Gaussian/Skew-T Weibull/Inverse-Gaussian
Number of study centers Number of study centers
Failure Probability 5 15 30 5 15 30
1% 0.53* 0.43* 0.29* 1.05 1.02 1.33
5% 0.59* 0.47* 0.38* 0.99 0.98 1.07
10% 0.76* 0.68* 0.62* 0.98 1.02 1.30
Table 3: Ratio of mean squared error of the proposed approach to the Weibull
random effect model when estimating the dose that causes failure at 1, 5 and
10%. Asterisks indicate the ratio is different from 1 at the 0.05 level.
5 Food Allergy Data
We apply the proposed approach to study two cumulative dose-to-failure failure
distributions for populations exposed to sesame and peanut allergies. These
databases and corresponding frequentist analyses using accelerated failure time
models are described in Taylor et al. [2014] and Dano et al. [2015]. For each indi-
vidual study in a given database, known or suspected allergic participants were
recruited and exposed to increasing doses of the allergenic food protein. For a
given dose, if no objective symptoms were observed after a set time period, the
dose was increased to the next dosing step until the first objective symptom(s)
of an allergic reaction was observed or the maximum predetermined experimen-
tal dose was reached. When objective symptoms were presented, the study was
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stopped, and the participant was marked as having an objective allergic reaction
between the previous cumulative dose with no objective symptoms (NOAEL,
No Observed Adverse Effect Level) and the current cumulative dose with ob-
served objective symptoms (LOAEL, Lowest Observed Adverse Effect Level).
Each individual study in a given database recruited participants from diverse
geographic populations and followed its own internal protocol determining the
nature and severity of symptoms required to terminate the experiment. As a
result, individual studies exhibit marked heterogeneity. We estimate the entire
failure distribution and utilize the entire distribution in certain quantitative risk
assessment scenarios. However, for the purposes of derivation of eliciting doses
which possibly could be used later as Reference Doses such as those proposed
the the Allergen Bureau of Australia and New Zealand’s Voluntary Incidental
Trace Allergen Labelling (VITAL) program Taylor et al. [2014], we are inter-
ested in the cumulative protein dose that would result in an objective allergic
reaction in less than 1% or 5% of the allergic population (i.e., ED01 or ED05)
which is important for risk assessment purposes. For our purposes, the two
databases analyzed represent a small database (three studies with less than 40
participants for sesame) and a large database (17 studies with more than 700
participants for peanut) to show the utility of the proposed approach. Analyses
for these databases use the same prior distributions as those in the simulation
study.
5.1 Peanut dose-to-failure
Taylor et al. [2014] reported 750 peanut-allergic individuals with 30 left-censored
and 132 right-censored datapoints. Using accelerated failure time models, cumu-
lative ED01 values were reported as 0.13 mg peanut protein for the Log-Logistic
distribution and 0.28 mg peanut protein for the Log-Gaussian distribution. Ac-
celerated failure time ED05s were 1.4 and 1.5 mg peanut protein, respectively,
with ED10s of 4.1 and 3.8 mg peanut protein. Based upon the available data
and expert judgement, there was no biological reason to distinguish between
the results of either distribution and the VITAL Scientific Expert Panel rec-
ommended a Reference Dose of 0.2 mg peanut protein to guide application of
precautionary allergen labeling and achieve the desired protection level for 99%
of the the allergic population Taylor et al. [2014]. However, this Reference Dose
has come into question as the process did not rely on a single dose distribu-
tion. Reanalysis of the Taylor et al. [2014] peanut database with the proposed
approach in this manuscript results in a stacked survival estimate ED01 of 0.2
mg peanut protein, an ED05 of 3.3 mg peanut protein and an ED10 of 10.9 mg
peanut protein. Unsurprisingly, the stacked survival estimate values are quite
close to the previous accelerated failure time results, and the stacked survival
estimate ED01 of 0.2 mg peanut protein is the same as the previously suggested
Taylor et al. [2014] VITAL reference dose of 0.2 mg peanut protein. The Weibull,
Generalized Pareto and Log-Laplace distributions were the 3 models giving the
most weight to the ED estimation for the peanut reanalysis. The Generalized
Pareto and Log-Laplace distributions were not previously available for Taylor
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Figure 2: Stacked posterior predicted failure distribution from 17 food challenge
studies estimating peanut protein allergies. Center black line is the stacked
central estimate, and the dashed black line represents the estimated 90% pos-
terior predicted failure times for the population. Red lines represent individual
Kaplan-Meier curves for the studies. The darker red curves represent studies
with more observations.
et al. [2014] or Dano et al. [2015], demonstrating the added value of the new
approach and reinforcing the conservative nature of the previous estimates.
5.2 Sesame dose-to-failure
Dano et al. [2015] reported 35 sesame-allergic individual datapoints. Using
accelerated failure time models, the lower 95% confidence interval estimates for
the cumulative ED05 values were reported as 0.4 mg sesame protein for the Log-
Logistic distribution, 0.6 mg sesame protein for the Log-Gaussian distribution,
and 0.1 mg sesame protein for the Weibull distribution. Accelerated failure
time ED05s were 2.1, 2.4, and 1.0 mg sesame protein, respectively. Based on a
similar but slightly smaller database, the VITAL Scientific Expert Panel utilized
the lower 95% confidence interval of the ED05 to recommend a Reference Dose
of 0.2 mg sesame protein Taylor et al. [2014]. Reanalysis of the Dano et al.
[2015] sesame database with the proposed approach in this manuscript results
in a stacked survival estimate ED05 of 5.1 mg sesame protein, with a lower 95%
confidence interval of 0.6 mg sesame protein. The stacked survival estimate
12
Figure 3: Stacked posterior predicted failure distribution from 3 food challenge
studies estimating sesame protein allergies. Center black line is the stacked
central estimate, and the dashed black line represents the estimated 90% pos-
terior predicted failure times for the population. Red lines represent individual
Kaplan-Meier curves for the studies, and the grey line is the estimated Kaplan-
Meier curve for the entire database. The darker red curves represent studies
with more observations.
values are quite close to the previous accelerated failure time results, and the
stacked survival estimate of the lower 95% confidence interval estimate for the
ED05 of 0.6 mg sesame protein is slightly higher that the previously suggested
reference dose of 0.2 mg sesame protein, and it is in 0.1 to 0.6 mg sesame protein
range from the 3 accelerated failure time model estimates. The Log-Laplace
distribution, which was not previously available for Taylor et al. [2014] or Dano
et al. [2015], was model giving the most weight to the ED estimation for the
sesame reanalysis, again demonstrating the added value of the new approach.
6 Discussion
We have presented a general framework for survival regression based upon stack-
ing, and have applied it to several dose-to-failure data-sets where it is of interest
to determine levels of exposure that do not typically elicit a response from a ma-
jority of the sensitized population. Although we have assumed random effects
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for our model to account for study-to-study variability, other modifications of
this approach can be envisioned. For example, if necessary, it is possible given
the framework to include fixed effects. In such a case, survival functions given
these covariates can be constructed from the posterior predictive distribution.
The major benefit of this approach is that it can incorporate any para-
metric failure distribution. Extensions to the model are straight forward, and
individual models can be added to the code provided in the appendix. Flex-
ible survival models, such as those described by Lambert et al. [2004] can be
included providing an additional layer of flexibility. Finally, though we have
shown the applicability of the methodology with regard to clinical data from
the field of food allergy, it is anticipated that the method has utility outside of
this domain. Additional possible domains of application could include medical
related time-to-tumor research, carcinogenicity experiments in animals, large
epidemiological studies, machine maintenance studies, estimation of dietary ex-
posure to contaminants or other fields where interval censored data is present.
For example, in the machine reliability literature, where accurate estimates of
the failure times in the tail are important, this methodology may be a useful
addition.
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